Geoffrey Porges
Stock Analyst at Leerink Partners
(1.49)
# 3,531
Out of 5,154 analysts
114
Total ratings
47.37%
Success rate
-1.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Maintains: Outperform | $36 → $49 | $22.11 | +121.62% | 9 | Mar 2, 2026 | |
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $27.05 | +107.02% | 10 | Dec 15, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $759.86 | +11.86% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $67.37 | -28.75% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $369.53 | -41.55% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $230.11 | -41.33% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $28.78 | -61.78% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $143.93 | -47.89% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $44.55 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $13.57 | -26.31% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $456.69 | -61.68% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $28.27 | +197.13% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $54.51 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $13.12 | +364.94% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $184.87 | - | 8 | Mar 16, 2017 |
Arcus Biosciences
Mar 2, 2026
Maintains: Outperform
Price Target: $36 → $49
Current: $22.11
Upside: +121.62%
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $27.05
Upside: +107.02%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $759.86
Upside: +11.86%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $67.37
Upside: -28.75%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $369.53
Upside: -41.55%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $230.11
Upside: -41.33%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $28.78
Upside: -61.78%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $143.93
Upside: -47.89%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $44.55
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $13.57
Upside: -26.31%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $456.69
Upside: -61.68%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $28.27
Upside: +197.13%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $54.51
Upside: -
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $13.12
Upside: +364.94%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $184.87
Upside: -